Anti-TNF Study Shows Patients Receiving Remicade Demonstrate Improvement

Patients with active moderate to severe rheumatoid arthritis inadequately responding to either etanercept (Enbrel) or adalimumab (Humira) and who were actively switched to REMICADE (infliximab) demonstrated significant improvement from baseline at week 10, and sustained response through week 26 in an open label study.
Earth Times